



SCS
Swiss Chemical
Society

Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Report: youngSCS visit to Anton Paar



One of the goals of the young Swiss Chemical Society (youngSCS) is to offer its members the opportunity to explore companies related to the field of chemistry. In line with this mission, on 7th of March 2025, youngSCS members visited the site of Anton Paar TriTec, located in Corcelles. Anton Paar is a leading company renowned for its precision laboratory instruments.

After a welcome breakfast, the day started with an engaging presentation of the company by Dr. Amir Zaim, Sales Team Leader at Anton Paar. He highlighted the company's extensive portfolio, emphasizing its long-standing commitment to precision and innovation. We also learned that a key aspect of Anton Paar's unique business model is its ownership by the charitable Santner Foundation, ensuring a focus on long-term sustainability. Additionally, the company has an integrated supply chain, minimizing dependency on external suppliers and ensuring high quality control.

Ms. Issa Thévenaz then guided our group through the production area and laboratories, offering a closer look at Anton Paar's advanced testing instruments. The tour featured:

- Tribology Testing: Using tribometers to evaluate friction, wear, and lubrication performance through linear, circular, and oscillatory motion.
- Calotest: A precise technique for determining coating thickness.
- Nanoindentation Testing: Measuring elastic recovery, hardness, and creep behavior, including bioindentors for biomedical materials such as contact lenses or prostheses.
- Scratch Testing: Characterizing scratch resistance and coating adhesion, demonstrated through a live experiment.

To ensure maximum accuracy, both the laboratory and instruments were equipped with an anti-vibration system.

The visit continued with an interactive session led by Dr. Amir Zaim, Nicolas Ogez-Paul, and David Burnand where participants had the opportunity to see various analytical instruments used in material characterization and quality control. The session covered techniques such as CO₂ measurement and oxidation stability testing, as well as FTIR spectroscopy. Different methods for size particle analysis were also introduced, including Dynamic Light Scattering (DLS) for nano and microscale measurements, laser diffraction for particle size distribution in both liquid dispersions and dry powders, and Dynamic Image Analysis for assessing particle shape and size. The tour concluded with a demonstration by David Burnand on a rheometer, illustrating the ability to analyze the mechanical behavior of complex fluids. Using a gel sample, he demonstrated how rheological measurements provide valuable information on material properties, such as viscosity and elasticity.


The visit continued with an interactive session led by Dr. Amir Zaim, Nicolas Ogez-Paul, and David Burnand where participants had the opportunity to see various analytical instruments used in material characterization and quality control. The session covered techniques such as CO₂ measurement and oxidation stability testing, as well as FTIR spectroscopy. Different methods for size particle analysis were also introduced, including Dynamic Light Scattering (DLS) for nano and microscale measurements, laser diffraction for particle size distribution in both liquid dispersions and dry powders, and Dynamic Image Analysis for assessing particle shape and size. The tour concluded with a demonstration by David Burnand on a rheometer, illustrating the ability to analyze the mechanical behavior of complex fluids. Using a gel sample, he demonstrated how rheological measurements provide valuable information on material properties, such as viscosity and elasticity.

Acknowledgments

The visit to Anton Paar TriTec provided a valuable opportunity for youngSCS members to explore both the company and its state-of-the-art scientific instrumentation. Thus, we would like to thank Anton Paar TriTec and its representatives for making this visit possible. In particular, Doïna Gachet for organizing the visit, Dr. Amir Zaim for the company presentation, Ms. Issa Thévenaz for the Anton Paar TriTec company tour, and Nicolas Ogez-Paul and David Burnand for the lab tour with hands-on experiments and software demonstrations.

Source: Antoine Etourneau & Maximilian Horn, youngSCS

4th Employment Surveys for European Chemists



EuChemS conducted three employment surveys (ESEC1 – ESEC3) between 2013 and 2020. The responses provided unique data. For example, the data showed that chemists have always been very satisfied with their jobs, that 54% of the respondents had never experienced gender pay inequality in their workplace and that 78% had never experienced sexual harassment at work (<https://doi.org/10.1002/chem.202401222>).

The full reports of the preceding Employment Surveys for European Chemists are freely available from Chemistry – A European Journal.

ESEC questionnaires are multiple choice. These questionnaires allow convenient backtracking of the conditions surveyed. They end with the request: "Is there anything else you would like to let us know?" There are no restrictions on the topic or length of the free-text response, as we want to get individual thoughts from the members of the chemical workforce and to learn about issues that might otherwise be neglected. In the case of ESEC3, the free-text responses together were over 6000 words, a clear indication of the issues that needed to be addressed.

EuChemS invites all members of the chemical workforce to participate in the 4th Employment Surveys for European Chemists. Completion of the survey should take 15 to 20 minutes. Deadline is June 20, 2025.

Go to the survey: <https://www.euchems.eu/4th-employment-survey-for-european-chemists-esec4/>

Go to the survey: <https://www.euchems.eu/4th-employment-survey-for-european-chemists-esec4/>

The Path to the 10th Framework Programme for Research and Innovation (FP10)



The discussions surrounding the 10th Framework Programme for Research and Innovation (FP10) have already begun, with preparations for its launch in January 2028. As the successor to Horizon Europe, FP10 will play a critical role in shaping Europe's future research and innovation landscape, addressing

pressing global challenges like climate change, technological advancement, and security.

A significant focus of the ongoing dialogue is how to strengthen the EU's research base while supporting a knowledge- and data-driven economy. Given the complex geopolitical and economic context, there is a growing emphasis on ensuring the EU's strategic autonomy, technological sovereignty, and global competitiveness through robust R&I policies.

The European Research and Innovation Committee (ERAC) has already outlined key strategic priorities for FP10. These include building on the successes of Horizon Europe by maintaining a strong focus on excellence, supporting the entire R&I value chain, and promoting collaboration between EU Member States, Associated Countries, and stakeholders. The committee also stresses the importance of aligning R&I investments with broader EU policy goals, including enhancing global competitiveness, supporting decarbonization, and increasing Europe's strategic autonomy.

The timeline for FP10 is already taking shape. In 2024, stakeholders have provided their input on the programme. ERAC has delivered its recommendations, and a High-Level Expert Group, chaired by former Portuguese Minister of Science, Technology and Higher Education Manuel Heitor, has been tasked with advising the European Commission. The result is the report, entitled 'Align, Act, Accelerate: Research, Technology and Innovation to boost European Competitiveness', which highlights the European added value of the EU framework programme for research and innovation (R&I), and puts forward twelve recommendations. Additionally, an interim evaluation of Horizon Europe will be published in spring 2025, providing valuable insights into the current programme's successes and challenges.

The European Commission plans to release its formal legislative proposal for FP10 by mid-2025, followed by negotiations in the Council and the European Parliament. The final adoption of FP10 is expected by the end of 2027, just before Horizon Europe concludes. This timeline will set the stage for the implementation of FP10 from 2028 onwards.

Source: www.magazine.euchems.eu, Chiara Capodacqua, EuChemS

HONORS, AWARDS, APPOINTMENTS

Surface Structure Prize for Karl-Heinz Ernst, Empa



Prof. Karl-Heinz Ernst, Distinguished Senior Researcher at Empa, Swiss Federal Laboratories for Materials Science and Technology, receives the Surface Structure Prize 2025 for his groundbreaking work on chiral molecules and chiral structures at surfaces.

The selected work is presented by the awardee as an invited lecture at the ICSOS meeting. The 14th International Conference on the Structure of Surfaces (ICSOS-14) will be held at TU Wien, Vienna, Austria, from June 2 to 6, 2025.

The prize is awarded to one (or jointly to two or three) scientist(s), for an outstanding body of work in the field of surface and interface structure. For joint awards, the bodies of work must be closely related, such as in close collaborations or competing developments. The selected work is presented by the awardee(s) as an invited lecture at the ICSOS meeting.

Source: *The 14th International Conference on the Structure of Surfaces (ICSOS-14)*

Prof. Detlef Günther and Prof. Maksym Kovalenko, both ETHZ, appointed new members of the SATW



This year, the Swiss Academy of Engineering Sciences SATW has added 19 new Full Members to its network. Each possesses an impressive track record in the engineering sciences.

Amongst others, two SCS members were honored and we like to congratulate Prof. Detlef Günther and Prof. Maksym Kovalenko for receiving this distinction.

View the full list of all 19 new elected SATW members 2025 on the website of the SATW.

Prof. Detlef Günther, ETH Zurich, has been appointed a Full Member of SATW in recognition of his groundbreaking scientific and industrial research into trace element analysis and micro-analysis as well as his defining leadership role and initiatives in knowledge and technology transfer.

Prof. Maksym Kovalenko, ETH Zurich and Empa, has been appointed a Full Member of SATW in recognition of scientific breakthroughs in perovskite-based nanocrystals and quantum dots with unique optoelectronic properties for a new era in display or quantum technologies.


SATW is a network of key figures from science and industry. Individuals who make a special contribution to furthering SATW's goals and/or the engineering sciences can be elected Full Members. All members are elected in a secret ballot of eligible voters in a procedure directed by the Nomination Committee.

19 new Full Members were elected in 2025, as a result of which SATW now has a total of 382 Full and 8 Honorary Members. The new members' election will be marked at the Annual Congress on 27 May by a certificate presentation ceremony.

Source: <https://www.satw.ch>

JOURNAL NEWS

Helvetica, Volume 108, Issue 3, March 2025



HELVETICA
chimica acta
WILEY-VHCA

Editorial

Introduction for the Special Collection in the Honor of *Scott Denmark*
Jeffrey Bode, Cathleen Crudden

Perspective

Thermoresponsive Nanocarriers Transduced by Inorganic Nanoparticles: Design Considerations and Applications in

Drug Delivery

Anamarija Nikoletić Mirela Maleković, Gül Kozalak, Cornelia G. Palivan, Oya Tagit

Research Article

Effect of Particle Size and Alloying with Gallium and Zinc in Copper Nanoparticles from *Ab Initio* Molecular Dynamics
Andreas Müller, Aleix Comas-Vives, Christophe Copéret


Synthesis of α -Fluoroketones from Carboxylic Acids via Decarboxylation of Fluorinated Malonates
Raffael Davenport, Rolandas Cibiras, Gabriel Schäfer

Structure and Magnetic Properties of a Series of Uranium Bis-Siloxide Complexes
Luciano Barluzzi, Ivica Zivkovic, Farzaneh Fadaei-Tirani, Rodolphe Clérac, Marinella Mazzanti

Threshold Photoelectron Spectrum of 3,4-Dimethylenecyclobutene

Emil Karaev, Dorothee Schaffner, Marius Gerlach, Tobias Preitschopf, Patrick Hemberger, Ingo Fischer

Launch of a New Chemistry Europe Journal: ChemFoodChem



On behalf of Chemistry Europe, we are proud to announce the launch of *ChemFoodChem*, a new open access journal showcasing vital, ground-breaking research that combines chemistry and food science from around the world. *ChemFoodChem* aims to advance the understanding of food chemistry, safety, sensory science, nutritional aspects, and

agricultural chemistry. Our editorial team is dedicated to the rapid dissemination of original research, empowering scientists to make meaningful impacts on global food challenges.

The involvement of the food chemistry divisions in Chemistry Europe partner societies is essential to the success of *ChemFoodChem*. Please keep them posted and encourage them to actively participate and contribute to the journal.

Source: <https://chemistry-europe.onlinelibrary.wiley.com>

INDUSTRIAL NEWS

Source: www.chemanager-online.com

Granules India Buys Swiss CDMO Senn Chemicals

February 26, 2025: Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed. The acquisition brings Senn's expertise in liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS), along with a strong CDMO business and established customer relationships across pharma, cosmetics, amino acid derivatives (AAD) & therapeutic segments to Granules' portfolio. According to Granules, the acquisition aligns with its vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics. Granules and Senn have been developing two GLP-1 based active pharmaceutical ingredients (APIs), and more peptide-based APIs are planned to be added to the portfolio, to be developed using Senn's R&D capabilities, the companies said. The acquisition marks Granules foray into CDMO segments, further strengthening its global footprint. With this transaction, the Hyderabad-headquartered pharma company wants to leverage Senn's European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for amino acid derivative (AAD), peptide fragments, and peptide-based therapeutics. Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients. Krishna Prasad Chigurupati, chairman and managing director of Granules India, said: "By entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn's expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality

peptide-based solutions globally." Rico Wiedenbruch, Senn Chemicals' chairman, added: "With Granules' scale, operational efficiency, and global reach in the pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics."

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

March 6, 2025: Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttentz near Basel. This investment is part of the company's growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing. According to CordenPharma, the facility will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale solid phase peptide synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects, with a total SPPS reactor capacity of more than 5,000 liters. The main construction and qualification phase is expected to take place between 2025 and 2027 and start of commercial activities are scheduled to begin in the first half of 2028, creating over 300 new jobs. Once fully operational, the Switzerland site – together with the ongoing expansions and additional greenfield capacity at the company's site in Colorado – will significantly enhance the company's production capabilities. In their US facility in Boulder, Colorado, both expansions to existing lines and the construction of a new greenfield production area have already begun in parallel to the Switzerland initiative, CordenPharma said. The expansion will more than double the existing SPPS reactor capacity at the site by adding additional 25,000 liters of SPPS capacity – bringing it to a total reactor capacity of >42,000 liters by 2028. Michael Quirnbach, CEO of CordenPharma, commented: "The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients."

Roche and Zealand Pharma Collaborate on Weight Management Drug

March 13, 2025: Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark's Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma's amylin analog as a standalone therapy as well as a fixed-dose combination with Roche's lead incretin asset CT-388. Petrelintide, currently in Phase 2 clinical development, is a long-acting amylin analog suitable for once-weekly subcutaneous administration. The available clinical data suggests its potential to become a best-in-class amylin monotherapy, with improved tolerability compared to current weight management treatments and to expand into adjacent indications, the companies said in a statement. As a part of this agreement, Zealand Pharma and Roche will co-commercialize petrelintide in the US and Europe, whereas Roche will obtain exclusive rights to commercialization in the rest of the world. Roche will be responsible for commercial manufacturing and supply. Zealand Pharma will receive upfront payments of \$1.65 billion, including \$1.4 billion due upon closing and \$250 million in the first two years of the collaboration. Zealand Pharma is also eligible for development milestones of \$1.2 billion primarily linked to initiation of Phase 3 trials with petrelintide monotherapy and sales-based milestones of \$2.4 billion, for a total consideration to Zealand Pharma of up to \$5.3 billion.

Profits and losses for petrelintide and petrelintide/CT-388 will be shared on a 50/50 basis in the US and Europe, and Zea-

land Pharma is eligible to receive royalties on net sales in the rest of the world. Zealand Pharma will pay Roche \$350 million, offsettable against milestone payments, for the petrelintide/CT-388 fixed-dose combination product or next-generation petrelintide combination products being pursued under the collaboration agreement. According to Roche, the combination of petrelintide with its dual GLP-1/GIP receptor agonist CT-388 will further strengthen and expand the Swiss company's pipeline in the field of cardiovascular, renal, and metabolic (CVRM) diseases. Teresa Graham, CEO of Roche Pharmaceuticals, commented: "We share the vision to develop petrelintide as a future foundational therapy. By combining petrelintide with our pharmaceuticals portfolio and with our diagnostics expertise in cardiovascular and metabolic diseases, we are aiming to transform the standard of care and positively impact patients' lives." Adam Steensberg, Zealand Pharma's CEO, added: "We strongly believe that petrelintide holds potential as a foundational therapy for weight management, addressing unmet medical needs among the majority of people living with overweight and obesity, both as stand-alone therapy and in combination with other agents." The closing of the transaction, which is subject to regulatory approvals and other customary closing conditions, is expected in the second quarter of 2025.

Data-Driven Enzyme Immobilization

Empowering Industrial Biocatalysis Through Data-Driven Development of Immobilized Enzymes

March 19, 2025: Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

CHEManager International: *What inspired your innovative idea, and what problem does it aim to solve?*

David Roura Padrosa: The idea for Inseit stemmed from recognizing the inefficiencies of the trial-and-error approaches in enzyme immobilization for biocatalyst development. Enzyme immobilization is a key technique, creating more stable and reusable biocatalysts, but it is still underused due to this. Other biotechnological fields also have the same combinatorial problem, for example enzyme engineering, and they have 'solved' it with data-driven approaches. So, we saw an opportunity to leverage computational tools and simulations to make enzyme immobilization faster and more predictable. Our innovation addresses critical bottlenecks in biocatalyst development, as development time and reliability are two of the main bottlenecks limiting the implementation of biocatalysis in industrial processes.

Can you describe the key features and benefits of your innovation?

D. Roura Padrosa: Our core innovation lies in both in silico and in vitro innovations. First, before going to the lab we apply our in silico design workflows and simulations to understand what guides the immobilization of the protein and what are the best strategies to try. After this in silico screening, we go to the wet-lab screening. Here, we have been developing for the last two years a semi-high throughput screening platform that allows us to test multiple immobilizations at once. In combination, both aspects allow us to be rational, faster and more effective in our development.

On the other hand, we have also been working on expanding the off-the-shelf offer of immobilized enzymes. Currently, you can find almost exclusively only hydrolytic enzymes, but, biocatalysis goes way beyond this. We offer a wide range of optimized immobilized enzymes: transaminases, imine-reductases, alcohol dehydrogenases, ketoreductases and more. And we are constantly expanding this catalogue because we want to speed up

the application of biocatalysis in R&D and production as much as possible.

What challenges did you face during the development of your innovation, and how did you overcome them?

D. Roura Padrosa: One challenge is from a technical aspect and the other is based on industry. From the technical perspective, one of our main challenges was creating accurate models to simulate immobilization, including protein-material interactions, as this is quite a new approach and very little has been done in this sense. We are getting better at this almost every week, with the new data created and refining our models and assumptions. On the other side, one thing that we had to consider since the beginning was scalability.

We are, ourselves, an R&D company but we know our solutions have to be applied at scale to have the impact we want. This is why, since the beginning, we have been looking for partnerships to ensure that what we can produce at the gram scale ourselves, could also be produced, in a fast manner, at the kilogram or ton scale.

How do you plan to bring your innovation to market, and what is your target audience?

D. Roura Padrosa: Our go-to-market strategy focuses on positioning Inseit as a trusted technology partner offering customized solutions for enzyme immobilization. Our initial target audience includes R&D teams in large biotech firms, pharma companies and even CDMOs who are looking to implement biocatalytic steps in their synthesis. We offer both CRO services, to develop customized solutions for our clients and direct sales of the products from our catalogue. Also, it's important to say that we don't stop there and part of our offering is also the application in continuous flow of the desired biocatalysts – a tailored solution or screening the ones we have in our catalogue.

What makes your innovation unique compared to existing solutions in the market?

D. Roura Padrosa: Inseit stands out because of its data-driven development. Time is crucial in development stages, and the fact that we can offer in silico planning of enzyme immobilization makes a difference for our clients. Unlike traditional methods that rely on extensive lab experiments, our technology significantly reduces the trial-and-error process. Our focus on tailored immobilizations and the wide offer in our catalogue is also unique, and it enables seamless integration of enzymes in multi-step synthesis.

Personal Profile

David Roura Padrosa is the CEO and co-founder of Inseit, a spin-off from the University of Bern. David earned his PhD at the University of Nottingham (UK), focused on the discovery, characterization and application of novel enzymes for the synthesis of key intermediates in continuous flow. Since 2022, with Inseit, he combines his expertise in biocatalysis and bioinformatics for the development of novel tools that can advance the implementation of biomanufacturing strategies at scale.

Next-Gen Immobilized Enzymes

Enzymes are powerful catalysts for the synthesis of key chemical intermediates, drugs, food ingredients, and biofuels. But on an industrial scale, they often suffer from rapid inactivation due to harsh reaction conditions, requiring careful evaluation of their cost-efficiency. Moreover, while enzymes excel in certain reactions, they must normally be integrated with up or downstream chemical processes, and in their free form, they can be difficult to incorporate effectively. This limits their widespread adoption despite their demonstrated potential for greener manufacturing, but industries worldwide need stable, reusable enzyme systems to

make their production processes both environmentally friendly and economically viable.

Inseit has developed a smart platform for enzyme immobilization to address these challenges. Its approach combines computer-based screening (in silico) with targeted lab testing (in vitro) to quickly identify optimal ways to immobilize enzymes in their most favorable conformation. This enhances enzyme performance, longevity, and reusability while making them more compatible with industrial processing requirements.

The company's tailored bioinformatic workflow sets it apart from conventional methods. It leverages data analytics, machine learning, and advanced simulations to predict optimal immobilization strategies before extensive laboratory testing, saving resources and accelerating time-to-market.

Inseit offers two commercial pathways: custom immobilization development services tailored to specific reaction requirements, and a growing catalog of ready-to-use immobilized enzymes designed for efficiency and versatility. Its products can be seamlessly integrated into existing production lines with minimal process adjustments.

Looking ahead, the company will expand its catalog and refine its technology to help industries adopt sustainable practices. Inseit's vision is to make enzymatic processes the preferred choice for green chemistry applications.

Towards the Integration of Industrial Biocatalysis

Recognizing the limitations of traditional approaches, the Inseit team developed a Data-driven method for enzyme immobilization. Since 2022, they have developed the in silico screening platform, secured key customers, and released the early catalogue of readily available immobilized enzymes. Looking ahead, Inseit is raising a second round of investment to scale its operations, expand the catalog and secure strategic partnerships with CDMOs for pilot projects.

Milestones

2021

Inseit was selected to participate in the international accelerator organized by Johnson Matthey and The Bakery (UK) and build upon the first open-source tools made available in 2022.

2022

Awarded a Bridge Proof of Concept grant from Innosuisse and Swiss National Science Foundation

Incorporation of Inseit in Bern, Switzerland after being awarded a Bridge Proof of Concept grant from Innosuisse and Swiss National Science Foundation.

2023

Inseit attracted the first round of angel investment after securing the first customer projects.

Awarded two prizes — Scientific Excellence and Novel Idea Award from the Nucleate Activator

2024

Inseit was selected as part of the Venture Leaders Biotech 2024, connecting with VCs, partners, and clients from the Boston ecosystem. Release of the first iteration of the catalogue of immobilized enzymes, focusing on cofactor recycling and auxiliary enzymes.

Roadmap

Inseit is seeking to establish new collaborations and proof of concept projects with leading CDMOs and fine chemical companies. Further to that, it is looking for strategic investment to ramp up its R&D capacity to both further develop the predictive capacity of our in silico screening tools and expand its catalogue of readily available immobilized enzymes.



ilmac
INSPIRING THE FUTURE OF
CHEMISTRY AND LIFE SCIENCES

SCS
Swiss Chemical
Society

Ilmac
Inspiring the Future of Chemistry
and Life Sciences
16.-18. September | Messe Basel
(Switzerland)

Ilmac Conference 2025
«Transforming Innovative R&D into
Sustainable Chemical Practices»

3 Symposia with lectures, discussion
panels and networking opportunities:

- 16. Sep: Artificial Intelligence (AI) and
Digital Methods
- 17. Sep: Sustainable Applied Methods and
Enabling Key Technologies
- 18. Sep: Biotech and Biomanufacturing -
Sustainability in Biotechnological
Processes and Products

Registration with prio code *scs-ilmac25*

Ilmac 365 – The Community Network
Ilmac.ch/365

Free ticket on
ticket.ilmac.ch/MCH/1A
SCS prio code:
scs-ilmac25

